Novartis (NOVN) Given a CHF 95 Price Target at Jefferies Financial Group
Novartis (VTX:NOVN) has been given a CHF 95 price target by analysts at Jefferies Financial Group in a research note issued on Thursday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the stock.
NOVN has been the subject of several other reports. Morgan Stanley set a CHF 80 target price on Novartis and gave the company a “sell” rating in a research report on Wednesday, April 10th. JPMorgan Chase & Co. set a CHF 85 target price on Novartis and gave the company a “sell” rating in a research report on Tuesday, April 9th. Deutsche Bank set a CHF 96 target price on Novartis and gave the company a “neutral” rating in a research report on Friday, January 11th. Credit Suisse Group set a CHF 84 target price on Novartis and gave the company a “neutral” rating in a research report on Friday, April 5th. Finally, HSBC set a CHF 86 price target on Novartis and gave the company a “neutral” rating in a research note on Wednesday, February 6th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of CHF 88.71.
Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
See Also: What is Put Option Volume?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.